Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
The ninth acquisition since 2018
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
The cash consideration for the above acquisition will be Euro 26 million.
Subscribe To Our Newsletter & Stay Updated
